Agile Therapeutics, Inc. (AGRX)
| Previous close | 0.3940 |
| Open | 0.3744 |
| Bid | 0.5833 x 200 |
| Ask | 0.5669 x 100 |
| Day's range | 0.3645 - 0.4000 |
| 52-week range | 0.2000 - 7.0000 |
| Volume | |
| Avg. volume | 729,745 |
| Market cap | 2.537M |
| Beta (5Y monthly) | 1.40 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -6.7100 |
| Earnings date | 09 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.00 |
Insider MonkeyAgile Therapeutics, Inc. (NASDAQ:AGRX) Q4 2023 Earnings Call Transcript
Agile Therapeutics, Inc. (NASDAQ:AGRX) Q4 2023 Earnings Call Transcript March 28, 2024 Agile Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-1.46 EPS, expectations were $-0.92. AGRX isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning, and welcome […]
- Thomson Reuters StreetEvents
Q4 2023 Agile Therapeutics Inc Earnings Call
Q4 2023 Agile Therapeutics Inc Earnings Call
GlobeNewswireAgile Therapeutics Reports Fourth Quarter & Full Year 2023 Financial Results and Provides Corporate Update
Full Year 2023 Net Revenue Increased 80% from 2022 While OPEX Decreased 33% Twirla Demand and Factory Sales Up 121% and 114% Respectively in 2023 vs 2022 Company Completes Pay-Off of Debt Facility in First Quarter 2024 Twirla Demand Expected to Rebound in First Quarter 2024 from Decreased Demand in Fourth Quarter 2023 Management to Host Conference Call Today, Thursday, March 28, 2024 at 8:30 a.m. ET PRINCETON, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Pink: AGRX), a wome
